3.6 million Medicare enrollees may become eligible for Wegovy, an anti-obesity drug, with potential $3B annual cost.

3.6 million Medicare enrollees may become eligible for coverage of Wegovy, an anti-obesity drug, according to a KFF analysis. The FDA approved Wegovy for reducing cardiovascular disease risk in overweight or obese adults without diabetes. However, Medicare's budget may be strained as it could cost nearly $3 billion annually and contribute to higher Part D premiums for all beneficiaries.

April 24, 2024
8 Articles

Further Reading